Grifols rolls out Flebogamma 10% DIF IVIG in US
Grifols said that approval from the US Food and Drug Administration (FDA) for Flebogamma 10% DIF was obtained in July 2010 and final approval in Europe is expected
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Rexahn Pharma said that the patent covers neurotherapeutic pharmaceutical formulation for cefazoline sulfone, cefazoline sulfoxide, ceftriaxone sulfoxide, and ceftriaxone sulfone for treating neurological disease and behavioral and cognitive